ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules [Yahoo! Finance]
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
ALX Oncology (ALXO) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $5.00 price target on the stock.
ALX Oncology (ALXO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $4.00 price target on the stock.